News for Healthier Living
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Substudy Supports Reduced Risk of Metastasis and Death
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -- plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.
The substudy, co-led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, was presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain and published today in European Urology.
October 26, 2026
October 29 2026October 28 2026October 27 2026October 26 2026October 25 2026October 24 2026October 23 2026October 22 2026October 21 2026October 20 2026October 19 2026October 18 2026October 17 2026October 16 2026
|
|
|
|
|